Literature DB >> 27814623

Molecular basis for prostate cancer racial disparities.

Santosh K Singh1, James W Lillard1, Rajesh Singh2.   

Abstract

Prostate cancer (PCa) remains the most common cancer in American men. African-American (AA) men continue to have higher PCa prevalence and mortality rates compared to men in other populations. In addition to socioeconomic factors and lifestyle differences, molecular alterations contribute to this discrepancy. We summarize molecular genetics research results interrelated with the biology of PCa racial disparity. Androgen and androgen receptor (AR) pathways have long been associated with prostate growth. Racial differences have also been found among variants of genes of the enzymes involved in androgen biosynthesis and metabolism. Growth factors and their receptors are a potential cause of the disparity in PCa. Recent molecular and biotechnological approaches in the field of proteomics and genomics will greatly aid the advancement of translational research on racial disparity in PCa, which may help, in finding new prognostic markers and novel therapeutic approaches for the treatment of PCa in AA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27814623      PMCID: PMC5550772          DOI: 10.2741/4493

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  192 in total

1.  A genomic scan of families with prostate cancer identifies multiple regions of interest.

Authors:  M Gibbs; J L Stanford; G P Jarvik; M Janer; M Badzioch; M A Peters; E L Goode; S Kolb; L Chakrabarti; M Shook; R Basom; E A Ostrander; L Hood
Journal:  Am J Hum Genet       Date:  2000-05-19       Impact factor: 11.025

2.  Blood vitamin d levels in relation to genetic estimation of African ancestry.

Authors:  Lisa B Signorello; Scott M Williams; Wei Zheng; Jeffrey R Smith; Jirong Long; Qiuyin Cai; Margaret K Hargreaves; Bruce W Hollis; William J Blot
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Novel mutations of epidermal growth factor receptor in localized prostate cancer.

Authors:  Diah A Douglas; Hong Zhong; Jae Y Ro; Carole Oddoux; Aaron D Berger; Matthew R Pincus; Jaya M Satagopan; William L Gerald; Howard I Scher; Peng Lee; Iman Osman
Journal:  Front Biosci       Date:  2006-09-01

4.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Authors:  F M Sirotnak; M F Zakowski; V A Miller; H I Scher; M G Kris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors.

Authors:  P Mathijs Voorhoeve; Carlos le Sage; Mariette Schrier; Ad J M Gillis; Hans Stoop; Remco Nagel; Ying-Poi Liu; Josyanne van Duijse; Jarno Drost; Alexander Griekspoor; Eitan Zlotorynski; Norikazu Yabuta; Gabriella De Vita; Hiroshi Nojima; Leendert H J Looijenga; Reuven Agami
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

6.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.

Authors:  F Modugno; J L Weissfeld; D L Trump; J M Zmuda; P Shea; J A Cauley; R E Ferrell
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

7.  Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study.

Authors:  R Heikkilä; K Aho; M Heliövaara; M Hakama; J Marniemi; A Reunanen; P Knekt
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

8.  Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men.

Authors:  Tomoko Sonoda; Hiromu Suzuki; Mitsuru Mori; Taiji Tsukamoto; Akira Yokomizo; Seiji Naito; Kiyohide Fujimoto; Yoshihiko Hirao; Naoto Miyanaga; Hideyuki Akaza
Journal:  Eur J Cancer Prev       Date:  2010-03       Impact factor: 2.497

9.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

Authors:  R K Ross; L Bernstein; R A Lobo; H Shimizu; F Z Stanczyk; M C Pike; B E Henderson
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

10.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

View more
  10 in total

Review 1.  Racial disparities, cancer and response to oxidative stress.

Authors:  Jie Zhang; Zhi-Wei Ye; Danyelle M Townsend; Chanita Hughes-Halbert; Kenneth D Tew
Journal:  Adv Cancer Res       Date:  2019-04-23       Impact factor: 6.242

2.  Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors.

Authors:  Oluwarotimi S Nettey; Austin J Walker; Mary Kate Keeter; Ashima Singal; Aishwarya Nugooru; Iman K Martin; Maria Ruden; Pooja Gogana; Michael A Dixon; Tijani Osuma; Courtney M P Hollowell; Roohollah Sharifi; Marin Sekosan; Ximing Yang; William J Catalona; Andre Kajdacsy-Balla; Virgilia Macias; Rick A Kittles; Adam B Murphy
Journal:  Urol Oncol       Date:  2018-09-17       Impact factor: 3.498

3.  Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.

Authors:  Stephen J Freedland; Adriana C Vidal; Lauren E Howard; Martha K Terris; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; William J Aronson
Journal:  Cancer       Date:  2017-06-27       Impact factor: 6.860

4.  Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.

Authors:  Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano
Journal:  Cancer Health Disparities       Date:  2020

5.  MYC DNA Methylation in Prostate Tumor Tissue Is Associated with Gleason Score.

Authors:  Kathryn Hughes Barry; Kareshma Mohanty; Patricia A Erickson; Difei Wang; Jianxin Shi; Gary Rose; Ashley Cellini; Kimberly Clark; Nicholas Ambulos; Jing Yin; Liying Yan; Matthew Poulin; Ann Meyer; Yuji Zhang; Søren M Bentzen; Allen Burke; Arif Hussain; Sonja I Berndt
Journal:  Genes (Basel)       Date:  2020-12-24       Impact factor: 4.096

Review 6.  A review of new hormonal therapies for prostate cancer in black men: is there enough data?

Authors:  Matthias E Meunier; Pascal Blanchet; Yann Neuzillet; Thierry Lebret; Laurent Brureau
Journal:  BMC Cancer       Date:  2021-01-14       Impact factor: 4.430

7.  Coexpression network analysis identified lncRNAs-mRNAs with potential relevance in African ancestry prostate cancer.

Authors:  Rafael Parra-Medina; Liliana López-Kleine; Sandra Ramírez-Clavijo; César Payán-Gómez
Journal:  Future Sci OA       Date:  2021-09-22

8.  Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.

Authors:  Katherine Emilie Rhoades Smith; Jacqueline Theresa Brown; Limeng Wan; Yuan Liu; Greta Russler; Lauren Yantorni; Sarah Caulfield; Jennifer Lafollette; Melvin Moore; Omer Kucuk; Bradley Carthon; Bassel Nazha; Mehmet Asim Bilen
Journal:  Oncologist       Date:  2021-06-29

9.  In Situ Analysis of N-Linked Glycans as Potential Biomarkers of Clinical Course in Human Prostate Cancer.

Authors:  Lindsey R Conroy; Alexandra E Stanback; Lyndsay E A Young; Harrison A Clarke; Grant L Austin; Jinze Liu; Derek B Allison; Ramon C Sun
Journal:  Mol Cancer Res       Date:  2021-06-15       Impact factor: 6.333

Review 10.  Health inequity drives disease biology to create disparities in prostate cancer outcomes.

Authors:  William G Nelson; Otis W Brawley; William B Isaacs; Elizabeth A Platz; Srinivasan Yegnasubramanian; Karen S Sfanos; Tamara L Lotan; Angelo M De Marzo
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.